What happened Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said on October 1, 2026, it entered the Sixth Amendment with Sanofi. Under the amendment, Sanofi will make a $1.0 billion upfront payment. The companies also agreed to co-develop and co-commercialize four new long-acting, Regeneron-invented antibodies that target IL-13, IL-4, IL-4R and IL-4xIL-13. Global profits on sales of

Central Pacific Bank Trust Division raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 90.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,687 shares of the biopharmaceutical company's stock after purchasing an additional 1,275 shares during the period.

Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Thursday shared clinical trial results for two investigational therapies targeting recurrent ovarian cancer and muscle loss prevention during weight management.

SNY and REGN expand their longstanding alliance to four new antibodies targeting type II inflammation, with billions in potential payments.

Rigel Pharmaceuticals (NASDAQ: RIGL - Get Free Report) and Regeneron Pharmaceuticals (NASDAQ: REGN - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation. Valuation and Earnings This table compares Rigel Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript

Regeneron and Sanofi announced a strategic expansion of their antibody collaboration, targeting IL-4/IL-13 pathways for next-generation inflammation and immunology therapies. The deal grants REGN $1B upfront and up to $7B in milestones, with a 50:50 global profit split for new assets, enhancing alignment and commercial potential. REGN and SNY now have several shots on goal to address Dupixent loss-of-exclusivity and emerging long-acting competitors, with key assets potentially launching from 2030 onward.

LGSOC is a biologically distinct variant of ovarian cancer, with limited treatment options, that is generally less responsive to conventional chemotherapy

In a predefined MRI substudy, trevogrumab prevented 70% of muscle loss associated with semaglutide treatment  A pre-specified subgroup analysis found that patients meeting the low lean mass definition for sarcopenia had greater loss of lean mass with semaglutide, and more preservation with trevogrumab Findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and is in press with The Lancet TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people living with obesity.